BURLINGAME, Calif.--(BUSINESS WIRE)--Juvaris BioTherapeutics, Inc., a biotechnology company developing therapeutics and adjuvanted vaccines for infectious diseases and cancer, today announced the initiation of a Phase 1 clinical trial of its lead compound, JVRS-100. The trial will compare the safety, tolerability and immunogenicity of the JVRS-100 adjuvant co-administered with a commercial influenza vaccine compared to vaccine alone.
